For the time being, the authors agreed that low-dose antiplatelet-therapy in pediatric ET should be started in case of symptoms (such as erythromelalgia, severe headaches, splenomegaly), in the presence of JAK2-mutations or other additional thrombophilic risk factors, and considered in case of persistent extremely elevated platelet counts (> 1000 × 109/l). The gene discussed is JAK2; the disease is Splenomegaly.